Chinese authorities fired two researchers and disciplined several others after an investigation found safety and ethical flaws in an experimental gene-editing study that led to the death of a child.
The two key researchers leading the study at Shanghai Jiao Tong University School of Medicine also were barred for five years from government science and technology projects, state media China Central Television reported on Friday.
The child’s death, first reported in late July by Science and Retraction Watch, drew scrutiny of China’s booming early-stage clinical trials, particularly those involving cell and gene therapies. Under China’s dual-track regulatory system, doctors at major hospitals can test certain novel therapies after local review, without approval from the national drug regulator.
Such studies, known as investigator-initiated trials, or IITs, have surged in recent years, accelerating the development of cutting-edge drugs that are fueling China’s biotech boom. But the July death — and two others that subsequently came to light in trials of therapies developed by Huidagene Therapeutics and RiboX Therapeutics — raised questions around whether oversight, safety reporting and public disclosure have kept pace with the sector’s rapid growth.
China finds ethical flaw in gene-editing trial that led to child’s death; two researchers fired
